Neurocrine Biosciences Inc. (NBIX) announced positive data for its Phase 2 clinical study of NBI-1117568 in adults with schizophrenia. NBI-1117568 is the first investigational, oral, muscarinic M4 selective agonist in development for the treatment of schizophrenia.
In Wednesday pre-market trade, NBIX was trading at $125.00 down $27.55 or 18.06%.
The NBI-1117568-SCZ2028 dose-finding study met its primary endpoint for the once-daily 20 mg dose. It demonstrated a statistically significant 7.5-point improvement in the the Positive and Negative Syndrome Scale (PANSS) total Score compared to placebo at week 6 with an 18.2-point PANSS total score improvement from baseline.
The once-daily 20 mg dose met additional endpoints, demonstrating statistically significant improvements in clinical global impression of severity scale and marder factor score positive symptom change and negative symptom change.
NBI-1117568 was generally safe and well tolerated at all doses studied in the Phase 2 clinical trial.
The Once-Daily 20 mg dose efficacy, safety and tolerability phase 2 results supported advancement to phase 3 in schizophrenia in early 2025.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.